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Mastocytosis (MC) denotes a heterogeneous group of
clinical disorders caused by abnormal growth and accumula-
tion of mast cells (incidence in the general population
presumably 7 new cases per 1,000,000 persons each year). It
ranges from primarily cutaneous manifestations of urticaria
pigmentosa to systemic mastocytosis (SM), in which virtually
every tissue can be involved, to rare malignant forms such as
mast cell leukemia.1Y3 Awell-established serum marker of SM
is tryptase (>- and A-tryptase forms). The current assays are
thought to measure pro-tryptase, resulting from continuous
release from mast cells in various organs (reference range,
G1Y11.4 ng/mL in our system).1Y3 In SM, tryptase levels
normally exceed 20 ng/mL. But as tryptase can also be
elevated because of other diseases (eg, myelodysplastic
syndrome), it is only a minor criterion for SM.1,3,4
Patients with SM are overrepresented in the group of
persons with anaphylaxis to Hymenoptera venom (prevalence
between 1% and 2.6%).1,2,5 As type 1 sensitization to venoms
detected by skin test or serology is reported to be compara-
tively low in some studies,1,4Y8 additional immunoglobulin E
(IgE)-independent pathways are thought to be important:
direct action of histamine-liberating or complement-activating
substances present in venom such as mast cellYdegranulating
peptide, mellitin, or phospholipases.6 In contrast to this, Rue¨ff
et al2 could demonstrate comparable speciﬁc venom sensitiza-
tion in patients after insect anaphylaxis with and without MC.
Generally, MC patients are endangered by life-threaten-
ing reactions after insect stings secondary to increased
mediator release.1,2,5Y7 Therefore, speciﬁc venom immu-
notherapy (VIT), the only available causal treatment of insect
venom hypersensitization so far, is urgently recommended. On
the other hand, these patients tend to express more serious side
effects,1,2,5,7Y9 in some cases, VIT even had to be stopped
prematurely.1,7 In addition to this, Dubois1 and the group of
Rue¨ff et al2 found an increased rate of sting reactions during or
after VIT in MC patients, even with fatal outcomes.9,10 These
data suggest that the efﬁcacy of VIT may be reduced in
patients with mastocytosis, particularly in vespid-allergic
patients.1,2,4 As ultrarush or rapid VIT (RVIT) has been
proven reliable and efﬁcacious with a low incidence of
systemic reactions,11,12 we chose this protocol for an MC
patient with wasp venom anaphylaxis.
The 41-year-old female patient had histologically
conﬁrmed cutaneous mast cell disease with typical urticaria
pigmentosa. Tryptase level was slightly elevated to 16.3 ng/mL
(average, about 5 ng/mL in controls), so that indolent SM was
also discussed, but a bone marrow biopsy was not feasible for
conﬁrmation.
In September 2003, she experienced an anaphylactic
reaction grade III to IV, including local and remote skin
reactions according to Mueller HL,13 lightheadedness,
hypotension, and dyspnea after a wasp sting. Although being
informed about the potentially higher risk, she explicitly
selected RVIT in January 2004 to reduce hospitalization time.
Four months later, she was checked for allergy status.
Total serum IgE was less than 10 IU/mL. The patient had no
history of atopy, and prick tests with perennial and seasonal
aeroallergens were negative. Bee venom remained negative in
prick test until 300 Kg/mL, whereas vespula venom was
positive here at 0.1 Kg/mL.
Intracutaneous tests were performed with serial 10-fold
dilutions of vespula venom. The end point concentration still
resulting in a positive reaction here was 0.00001 Kg/mL. The
initial wasp-speciﬁc IgE was 2 kU/L (class 2) (CAP Test,
Fa. Phadia, Sweden), and speciﬁc IgG resulted in 11.5 mg/L
(= intermediately elevated).
The VIT followed a modiﬁed ultrarush protocol14
(Table 1), with a subcutaneous injection of 0.00001 Kg wasp
venom (Venomil wasp, Fa. Bencard, Munich, Germany) and
increasing doses 10-fold every 30 minutes until 10 Kg,
followed by 20, 30, 50, and 100 Kg in 30-minute intervals. The
maximum single dose of 100 Kg was reached after 12 hours
with only local side effects.
The patient was pretreated with intravenous dimetindene
6 mg just before VIT. On day 2, she was discharged. Booster
injections of 100 Kg were given at 7, 14, and 21 days, and then
every 4 weeks on an outpatient basis.
In Figure 1, both the increase of wasp-speciﬁc IgG and
the continuous decrease of speciﬁc IgE from class 2 to below
detection limit after 18 months of therapy are presented. In
August 2004, the patient has tolerated a natural wasp sting
with only local symptoms.
TABLE 1. Rapid VIT Treatment Protocol for Updosing of Wasp










0 0.00001 None 128/80; 109
0.5 0.0001 None 138/79; 108
1 0.001 None 131/90; 107
1.5 0.01 None 120/88; 101
2 0.1 Mild erythema, 1 cm 129/79; 114
2.5 1 Wheal and flare, 3 cm 116/86; 116
3 10 Mild erythema, 1 cm 137/87; 123
4 20 None 106/67; 106
5 30 None 114/72; 109
6 50 None 112/62; 103
12 100 Erythema, 2 cm 115/81; 99
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No severe side effects were seen over a treatment period
of more than 2 years until VITwas discontinued in July 2006
because of pregnancy on the advice of the gynecologist. The
patient now continues to do well after VIT has been restarted
with a short modiﬁed rush of wasp venom from 0.01 to 100 Kg
for 4 hours. Interestingly, speciﬁc IgE had still been very
low after 1 year of cessation of treatment, but speciﬁc IgG
had dropped to almost the initial level. It increased again to
27.2 mg/L after 4 months of treatment (Fig. 1).
As classic IgE-mediated allergic reactions are under-
represented in patients with MC combined with insect
hyperreactivity,1,4Y7 it was speculated that binding of total
and speciﬁc IgE to abundant tissue mast cells could be
responsible for low serum levels.7,15 Many authors decided to
perform immunotherapy anyhow, independent of allergy test
results, because even if serology is negative, signiﬁcant levels
of venom speciﬁc IgE may still be present at the mast cell
and tissue level.6Y8 In some patients, MC is ﬁrst diagnosed
through a life-threatening insect sting anaphylaxis,5,7 and
other therapeutical options are not at hand.
Conventional VIT normally reaches the maintenance
dose of about 100 Kg or cumulative doses between 100 and
500 Kg venom protein after several weeks to months, whereas
rush-regimen use schedules between 5 and 10 days.8,11,12
The ﬁrst ultrarush protocol dates back to 1983, where Van
der Zwan et al14 performed a hyposensitization to wasp
venom within 6 hours in 11 patients without systemic reac-
tion. Ultrarush or rapid VIT use induction schemes between
90 minutes and 2 days.11,12 So far, no standard rapid or
ultrarush VIT protocol has been widely adopted. Patients with
a positive sting challenge after VIT may be protected by
increased maintenance dose.2 Some authors propose lifelong
VIT in MC because of the higher risk of severe relapses.2,4
Rapid VIT was well tolerated in our case and provided
protection against a ﬁeld sting. We documented a decrease of
speciﬁc IgE and increase in speciﬁc IgG, which has a proposed
blocking antibody mechanism.14
The rationale for us to choose RVIT was the results of
McHugh et al,16 who demonstrated a rapid decrease of
interleukin 4 during the ﬁrst treatment hours and a shift from
Th2 to a Th1 pattern, which was interpreted as an early
mechanism of immune modulation.
In summary, with this case, we present for the ﬁrst time
an ultrarush speciﬁc immunotherapy (= rapid VIT) within
12 hours in a patient with histologically conﬁrmed MC after
anaphylactic reaction to a vespid sting. We concluded that
even in these high-risk patients, RVIT could serve as a safe and
effective treatment, reducing the cost and time commitment,
promising a favorable patient compliance. Although it must be
pointed out that the tolerance of ultrarush VIT in a larger series
of MC patients, especially with proven systemic form or with
more severe sting anaphylaxis, is still unknown, and therefore,
caution is indispensable. The optimal duration and main-
tenance dosage of RVIT for MC patients need further
evaluation as well.
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